2 billion! Another IVD company received high investment

Medical Network August 3rd In the rapid growth of the IVD industry, another company has received high investment.

On August 1, Beijing Kemei Biotechnology Co., Ltd. received 2 billion yuan investment from Huaxing, Honghui, etc., which may refresh the unlisted IVD. enterprise A single maximum amount of financing record. According to the external press release, this transaction is the largest private equity transaction in China's in vitro diagnostic field in recent years.

It is reported that Kemei Bio is an in vitro diagnostic chemiluminescence enterprise. It was established in 1999 and has a history of 19 years of growth. Kemei has created a new market for 'infectious diseases eight', in the domestic chemiluminescence enterprise infectious disease detection. Leading the field.

Cypress Blue Instruments learned that in December 2007, Kemei Bio Angels raised $5 million in financing, and the investors did not disclose it. In December 2008, the company received $16 million in Series A financing, including Softbank China, USA. Zhongjinghe, Siemens Venture Capital.

After 10 years of growth in August 2018, the current round of financing is nearly 2 billion yuan. The investors include Huaxing Medical Industry Fund, Honghui Capital, Jingwei China, Ping An Innovation Investment Fund, Shanghai Free Trade Zone Fund, and Zhongjin Kangrui Medical Industry. Fund, Junlian Capital.

In addition to investing in Kemei Biological, Junlian Capital also invested in third-party medical testing institution Jinyu Medicine in 2008, and has become one of the largest users of IVD reagents in China.

Previously, in September 2017, Shanghai Lian Ying had raised 3.3 billion yuan. medical instruments The industry's largest financing. Earlier, in September 2016, Kangda Medical completed a financing of 1 billion yuan, which is also a large-scale financing case in the industry.